| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BIOL | Common Stock | Purchase | $798K | +1.31M | +13.58% | $0.61* | 10.9M | Feb 11, 2020 | Direct | F1 |
| transaction | BIOL | Common Stock | Sale | -$1.02M | -1.85M | -16.89% | $0.55* | 9.09M | Jun 8, 2020 | Direct | F1, F2 |
| transaction | BIOL | Common Stock | Sale | -$1.15M | -2.14M | -23.52% | $0.54* | 6.95M | Jun 9, 2020 | Direct | F1, F3 |
| transaction | BIOL | Common Stock | Sale | -$954K | -1.73M | -24.94% | $0.55* | 5.22M | Jun 10, 2020 | Direct | F1, F4 |
| transaction | BIOL | Common Stock | Conversion of derivative security | $1.5M | +3.75M | +71.78% | $0.40* | 8.96M | Jul 28, 2020 | Direct | F1 |
| transaction | BIOL | Common Stock | Sale | -$21.3K | -71.1K | -0.79% | $0.30 | 8.89M | Nov 24, 2020 | Direct | F1 |
| transaction | BIOL | Common Stock | Sale | -$58.9K | -203K | -2.28% | $0.29 | 8.69M | Nov 25, 2020 | Direct | F1 |
| transaction | BIOL | Common Stock | Sale | -$335K | -1.12M | -12.83% | $0.30 | 7.57M | Nov 30, 2020 | Direct | F1 |
| transaction | BIOL | Common Stock | Sale | -$360K | -1.2M | -15.85% | $0.30 | 6.37M | Dec 4, 2020 | Direct | F1 |
| transaction | BIOL | Common Stock | Sale | -$25.4K | -90.6K | -1.42% | $0.28 | 6.28M | Dec 16, 2020 | Direct | F1 |
| transaction | BIOL | Common Stock | Sale | -$160K | -573K | -9.12% | $0.28 | 5.71M | Dec 17, 2020 | Direct | F1 |
| transaction | BIOL | Common Stock | Sale | -$52.6K | -188K | -3.29% | $0.28 | 5.52M | Dec 18, 2020 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BIOL | Series F Convertible Preferred Stock | Award | +1.5K | 1.5K | Jul 22, 2020 | Common Stock | 3.75M | $0.40 | Direct | F1, F5, F6 | |||
| transaction | BIOL | Warrants | Award | +3.75M | 3.75M | Jul 22, 2020 | Common Stock | 3.75M | $0.40 | Direct | F1, F5 | |||
| transaction | BIOL | Series F Convertible Preferred Stock | Conversion of derivative security | -1.5K | -100% | 0 | Jul 28, 2020 | Common Stock | 3.75M | $0.40 | Direct | F1, F6, F7 |
Schuler Education Foundation is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | This late filing is due to inadvertent administrative error. |
| F2 | The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5399 and $0.5643, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. |
| F3 | The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5430 and $0.5601, inclusive. |
| F4 | The sale price reported is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.5485 and $0.5656, inclusive. |
| F5 | In connection with a public offering by the Issuer, on July 22, 2020, the Reporting Person acquired (i) 1,498 shares of Series F Convertible Preferred Stock, each of which is convertible into 2,500 shares of Common Stock, for a total of up to 3,745,000 shares of Common Stock, and (ii) 3,745,000 Warrants, each of which is exercisable to purchase one share of Common Stock, for a total of up to 3,745,000 shares of Common Stock, for an aggregate purchase price of $1,500,000. |
| F6 | Each share of Series F Convertible Preferred Stock is convertible at the Issuer's option at any time on or after July 22, 2021 or at the option of the Reporting Person at any time. |
| F7 | On July 28, 2020, the Reporting Person converted 1,498 shares of Series F Convertible Preferred Stock into 3,745,000 shares of Common Stock. |